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OBJECTIVE — To evaluate the efﬁcacy, safety, and tolerability of incremental doses of albi-
glutide, a long-acting glucagon-like peptide-1 receptor agonist, administered with three dosing
schedules in patients with type 2 diabetes inadequately controlled with diet and exercise or
metformin monotherapy.
RESEARCH DESIGN AND METHODS — In this randomized multicenter double-
blind parallel-group study, 356 type 2 diabetic subjects with similar mean baseline characteris-
tics (age 54 years, diabetes duration 4.9 years, BMI 32.1 kg/m
2, A1C 8.0%) received
subcutaneous placebo or albiglutide (weekly [4, 15, or 30 mg], biweekly [15, 30, or 50 mg], or
monthly [50 or 100 mg]) or exenatide twice daily as an open-label active reference (per labeling
in metformin subjects only) over 16 weeks followed by an 11-week washout period. The main
outcome measure was change from baseline A1C of albiglutide groups versus placebo at week
16.
RESULTS — Dose-dependent reductions in A1C were observed within all albiglutide sched-
ules. Mean A1C was similarly reduced from baseline by albiglutide 30 mg weekly, 50 mg
biweekly (every 2 weeks), and 100 mg monthly (0.87, 0.79, and 0.87%, respectively)
versus placebo (0.17%, P  0.004) and exenatide (0.54%). Weight loss (1.1 to 1.7 kg)
was observed with these three albiglutide doses with no signiﬁcant between-group effects. The
incidence of gastrointestinal adverse events in subjects receiving albiglutide 30 mg weekly was
less than that observed for the highest biweekly and monthly doses of albiglutide or exenatide.
CONCLUSIONS — Weeklyalbiglutideadministrationsigniﬁcantlyimprovedglycemiccon-
trol and elicited weight loss in type 2 diabetic patients, with a favorable safety and tolerability
proﬁle.
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E
arly intervention to improve glyce-
mic control reduces microvascular
complications in type 2 diabetes
(1–4) and may provide long-term macro-
vascular beneﬁts (5). Despite numerous
available therapies, over half of patients
with type 2 diabetes are unable to achieve
theAmericanDiabetesAssociation(ADA)
targetA1Clevel(7%)(6–8).Moreover,
weightgainandtreatment-inducedhypo-
glycemic episodes (9,10) are major barri-
ers to achieving glycemic control (10).
Antidiabetic therapies based on glu-
cagon-like peptide-1 (GLP-1) retain the
ability of native GLP-1 to stimulate glu-
cose-dependent insulin secretion and
suppress inappropriately elevated gluca-
gon secretion (11,12). Native GLP-1 also
slows gastric emptying and reduces food
intake, which leads to modest weight loss
(11). However, native GLP-1 is rapidly
inactivated (half-life 1–2 min) by dipepti-
dylpeptidase-4(DPP-4),limitingitsther-
apeuticpotential(13).Exenatide(half-life
2.4 h) improves glycemic control in com-
bination with metformin, a sulfonylurea,
or a thiazolidinedione (14–18). Despite
modest weight loss and improved glyce-
mic control, gastrointestinal (GI) intoler-
ability and twice-daily administration
may lead to discontinuation (19).
Albiglutide (formerly known as alb-
ugon) is a GLP-1 receptor agonist devel-
oped through the fusion of two repeats of
human GLP-1 (7–36) molecules to re-
combinant human albumin (20). The
GLP-1 dimer was used to avoid potential
reductions of the interaction of the GLP-1
moiety of the monomer with its receptor
in the presence of albumin. A single
amino acid substitution (ala83gly) ren-
ders the molecule resistant to DPP-4. The
structure of albiglutide provides an ex-
tended half-life (5 days), which may al-
low weekly or less frequent dosing.
Furthermore, albiglutide is relatively im-
permeant to the central nervous system
(21), which may have implications for GI
tolerability. In nonclinical studies, albig-
lutide stimulated cAMP production
through the GLP-1 receptor and induced
insulin secretion from INS-1 cells in vitro
and in animal models (21–22). It also de-
layed gastric emptying and reduced food
intake in rodents (21–23).
This study was designed to explore a
wide range of doses (4–100 mg) and
schedules (weekly to monthly) to assess
glycemic control and adverse event pro-
ﬁles for albiglutide. Exenatide was in-
cluded as an open-label reference to
provide clinical perspective for a GLP-1
receptor agonist.
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METHODS— This phase II trial was a
prospective randomized double-blind pla-
cebo-controlled parallel-group study con-
ducted between April 2007 and May 2008
at 118 sites in the U.S. (n  106), Mexico
(n  9), Chile (n  2), and the Dominican
Republic (n1) (online appendix 1, avail-
able at http://care.diabetesjournals.org/cgi/
content/full/dc09-0366/DC1). Men and
women of non-childbearing potential (age
18–75 years) were eligible for inclusion if
diagnosed with type 2 diabetes 3 months
before screening. Subjects were drug naïve
(diet and exercise) or treated with met-
formin monotherapy and stable for 3
months before prescreening (1 week prior
to screening visit). Only subjects treated
with metformin monotherapy were eligible
fortheexenatidearm(consistentwithlabel-
ing). Additional inclusion criteria included
BMI 20 and 40 kg/m
2 and A1C at
screening 7 and 10%.
Exclusion criteria included any oral
antidiabetic monotherapy (except met-
formin) 3 months prior to screening or
insulin 1 month prior to screening and
not used for 7 days; pancreatitis within
5 years; signiﬁcant cardiovascular, cere-
brovascular, renal, or hepatobiliary dis-
eases; fasting serum triglycerides 800
mg/dl (9 mmol/l) at screening; or hema-
tological proﬁles considered to be clin-
ically signiﬁcant. Lipid-lowering
medications must have been maintained
at the same dose for 3 months prior to
enrollment, and no prescription or over-
the-counter weight-loss drugs were
permitted.
The study protocol was approved by
an institutional review board and con-
ducted in accordance with the Declara-
tion of Helsinki. Written informed
consent was obtained from all subjects at
prescreening. A data safety monitoring
committee of independent experts as-
sessed safety data on an ongoing basis.
Randomization
Subjects were randomized into 1 of 10
treatment arms: double-blind placebo
(matched to albiglutide arms); albiglutide
weekly (4, 15, or 30 mg), every 2 weeks
(biweekly; 15, 30, or 50 mg), or monthly
(50 or 100 mg); or open-label exenatide
(5 g twice daily for 4 weeks followed by
12 weeks of 10 g twice daily). Albig-
lutide (formulated in 10 mmol/l sodium
phosphate, 4.2% trehalose, 2.8% manni-
tol, 0.01% polysorbate-80) and placebo
(same formulation without active princi-
ple) were administered in the physician’s
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jects receiving 4 mg albiglutide were
given 1.0 ml (4 mg/ml solution). Subjects
receiving 15, 30, or 50 mg albiglutide
were given 0.32, 0.65, or 1.0 ml (50
mg/ml solution). Subjects receiving 100
mg albiglutide were given two 1.0-ml in-
jections (50 mg/ml solution, 1 inch
apart). Placebo volumes were matched to
active treatment. Albiglutide/placebo in-
jections were subcutaneous to the abdo-
men using 30-G needles. Subjects were
observed for 30 min to monitor for in-
jection site reactions. Subjects receiving
exenatide initiated treatment in the phy-
sician’s ofﬁce and subsequently self-
administered according to the package
insert.After16weeks,subjectsenteredan
11-week washout phase to assess safety
and immunogenicity.
Assessments
On therapy. A1C and fasting plasma glu-
cose (FPG) measurements were per-
formed at screening, baseline, and weeks
2(FPGonly),4,5,7,8,9,12,15,and16.
Fasting fructosamine, C-peptide, gluca-
gon, insulin, and lipids were measured at
baseline and weeks 5, 8, 12, and 16.
	-Cell function was calculated using ho-
meostasis model assessment (24).
Adverse event assessments and safety
analyses were conducted throughout the
study. Nausea and vomiting were moni-
tored for occurrence and duration. Im-
munogenicity samples were taken at
baselineandweeks1,4,8,12,and16and
were screened for anti-albiglutide anti-
bodies via ELISA (20). Plasma samples
were collected to characterize the phar-
macokinetics of albiglutide, quantiﬁed by
ELISA (20) at baseline and at weeks 4, 5,
7, 8, 9, 12, 15, and 16. Population phar-
macokinetics analysis was performed us-
ing a nonlinear mixed-effect modeling
approach with NONMEM software
(ICON Development Solutions, Ellicott
City, MD).
Eleven-week washout. A1C, FPG,
and albiglutide concentrations were ob-
tained at weeks 17, 18, 20, 23, and 27;
fasting fructosamine, C-peptide, gluca-
gon, insulin, and lipid proﬁles were ob-
tained at weeks 20 and 27; and
immunogenicity assessments were exam-
ined at weeks 20, 23, and 27.
Statistical analysis
The primary objective was to evaluate the
doseresponseofalbiglutideforsafetyand
efﬁcacy.With30subjectsplannedineach
arm, a two-sided 95% CI for each group
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Figure 1—Effects of albiglutide on glycemic parameters. A: The reduction in A1C from baseline
at16weeks.Dataarepresentedasmeanchangefrombaseline(–SE).B:Theproportionofsubjects
achieving ADA A1C target of 7%. Data are presented as % at goal. C: Change in fasting plasma
glucoseovertime.Dataarepresentedasmeanchangefrombaseline(SE).*Noformalstatistical
comparisons versus exenatide (open label) were conducted. †P  0.05 vs. placebo.
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on the A1C scale, assuming a standard
deviation of 1.00%.
The primary efﬁcacy end point was
change from baseline A1C at week 16 ver-
sus placebo across different doses within
each schedule (weekly, biweekly, and
monthly).TheprimaryanalysiswasanAN-
COVA model with main effects for group
and prior metformin therapy, adjusting for
baseline A1C. Dose response was evaluated
usingcontrastswithintheANCOVAmodel
framework. Pairwise comparisons were
performed in the same ANCOVA model.
Secondary end points were similarly ana-
lyzed. Responder analysis and incidence of
hypoglycemia were summarized by group
statistics. No formal statistical comparisons
versus exenatide were conducted. Safety
and tolerability data were categorically
collected.
Comparisons were made on the intent-
to-treatpopulation,deﬁnedasallrandomly
assignedsubjectswithatleastonepostbase-
line assessment of the primary end point,
using last observation carried forward. The
safety population included all randomized
subjects who received at least one dose of
any medication. An interim analysis was
conducted at 8 weeks for administrative
purposesbyanindependentstatisticalanal-
ysis group; blinding was retained for study
investigators and study personnel with
daily operational responsibility. No formal
interim inferential hypothesis testing was
conducted; the study conduct was unal-
tered based on the results of the interim
analysis.
RESULTS
Subject disposition and baseline
characteristics
A total of 774 subjects were screened. Of
361 subjects randomized, 356 received
treatment and were included in the safety
analysis, 345 were included in the efﬁcacy
analysis, and 255 completed the 16-week
trial. Withdrawal rates were similar across
groups (online appendix 2); the most fre-
quent reason for withdrawal was adverse
events. Adverse events occurring in at least
one subject leading to withdrawal included
hyperglycemia (0–11.8%, n  24, mostly
in placebo and lower-dose groups), GI
events (0–11.4%, n  10, across groups),
injection site events (0–9.7%, n  11,
mostly in higher-dose groups), and hyper-
triglyceridemia (0–5.7%, n  2o f3 5r e -
ceiving50mgalbiglutidebiweekly,deemed
unrelated to study drug; 0% in other
groups). Other reasons for withdrawal in-
cluded loss to follow-up, protocol viola-
tions, and voluntary withdrawal.
Baseline demographics and charac-
teristics were comparable across groups
(onlineappendix3).Meandurationofdi-
abetes was 4.9 years. Baseline A1C levels
(mean 8.0%) were evenly distributed
across arms. A similar proportion of sub-
jectsreceivingplacebooralbiglutidewere
drug naïve (25.7–34.4%) or receiving
metformin monotherapy. All subjects re-
ceiving exenatide were on metformin
monotherapy. The groups were similar in
termsofrace/ethnicity(43.8–71.0%Cau-
casian; 87.1 and 12.9% of subjects were
from U.S. and Latin American clinics, re-
spectively), and the rates of dyslipidemia,
hypertension,andcoronaryarterydisease
were 50.0–80.0, 47.1–67.6, and
0–15.2%, respectively.
Efﬁcacy
After 16 weeks, albiglutide signiﬁcantly
reduced A1C in a generally dose-
dependent manner within each dose
schedule (Table 1) (Fig. 1A). Mean A1C
reductions from baseline in subjects re-
ceivingthehighestdoseineachtreatment
schedule were 0.87, 0.79, and
0.87% for 30 mg weekly, 50 mg bi-
weekly, and 100 mg monthly, respec-
tively, versus placebo (0.17%) or
exenatide (0.54%). A1C reductions
(based on ANCOVA model) for the high-
est doses compared with placebo were
statistically signiﬁcant: 30 mg weekly,
0.62% (95% CI 1.03 to 0.22), P 
0.003; 50 mg biweekly, 0.57% (0.96
to 0.19), P  0.003; and 100 mg
monthly, 0.60% (0.99 to 0.22),
P  0.002. Numerically greater reduc-
tions in A1C were observed in subjects
with baseline A1C 8.5%.
The proportion of subjects achieving
the ADA target A1C (7.0%) at week 16
increased with increasing doses of albig-
lutide within each schedule; similar pro-
portions of subjects achieved target A1C
at the highest albiglutide dose among the
three schedules. More subjects receiving
albiglutide 30 mg weekly (52%), 50 mg
biweekly (53%), and 100 mg monthly
(48%) achieved A1C 7.0% compared
with subjects receiving placebo (20%)
and exenatide (35%) (Fig. 1B).
The time course of albiglutide-
induced changes in FPG demonstrated
that each schedule elicited a dose-
dependent FPG reduction over 16 weeks,
with no changes in FPG observed with
placebo. Rapid reductions in FPG were
observed, with similar FPG reductions at
the 16-week end point for each of the
highest doses (Fig. 1C). Statistically sig-
niﬁcant reductions were seen for FPG
compared with placebo at week 16
(1.38 mmol/l [P  0.02], 1.16
mmol/l [P  0.03], and 1.17 mmol/l
[P  0.03] for 30 mg weekly, 50 mg bi-
weekly, and 100 mg monthly albiglutide
doses, respectively). The 4- and 15-mg
weekly dose regimens of albiglutide re-
duced FPG but were less effective. The
greatest ﬂuctuations in FPG over time
were observed in subjects receiving albi-
glutide 100 mg monthly (Fig. 1C). Ex-
enatide was associated with a relatively
consistent FPG proﬁle over time that was
numerically less than FPG reductions
seen with the highest doses of albiglutide
(Fig. 1C).
Neither fasting insulin nor glucagon
levelswereconsistentlyorsigniﬁcantlyal-
tered.Smallimprovementsin	-cellfunc-
tion (assessed by homeostasis model
assessment of 	-cell function) were noted
in subjects receiving albiglutide (online
appendix 4).
There was no signiﬁcant difference in
weight reduction among groups. A con-
sistent trend in weight reduction was
noted with average weight loss ranging
from 1.1 to 1.7 kg in subjects receiv-
ing the highest albiglutide dose in each
schedule. These reductions were numer-
ically greater than those for subjects re-
ceiving placebo (0.7 kg) but less than
those for subjects receiving exenatide
(2.4 kg). Albiglutide and exenatide
tended to reduce mean systolic and dia-
stolic blood pressure but did not signiﬁ-
cantly change the plasma lipoprotein
proﬁle (online appendix 4).
Safety and tolerability
The percentage of subjects reporting at
least one adverse event was similar across
groups (67–85%). The most frequently
reported adverse events included nausea
(11.8–54.3%), vomiting (0–41.2%),
headache (5.9–23.5%), dizziness (5.7–
14.3%), nasopharyngitis (5.7–11.4%),
back pain (0–14.3%), inﬂuenza (0–
9.7%), upper respiratory tract infections
(0–15.2%),andlocalskinreactions(2.9–
28.6%) (online appendix 5).
Theproportionofsubjectswhoexpe-
rienced nausea and/or vomiting was
lower with administration of 30 mg al-
biglutide compared with the proportion
of subjects receiving higher doses. In the
30-mg weekly arm, 29.0% of subjects ex-
perienced nausea and/or vomiting, com-
pared with 54.3% in the 50-mg biweekly
Rosenstock and Associates
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group. The percentage of exenatide sub-
jects who experienced nausea and/or
vomiting also was higher (45.7%) than in
the 30-mg weekly albiglutide group.
Examination of the time course (Fig.
2)ofnauseaand/orvomitingrevealedthat
the proportion of subjects experiencing
theseadverseeventseachweekwaslowin
the 30-mg weekly arm (10%) and de-
clined over the course of the study, with
no reports of nausea or vomiting after 8
weeks (Fig. 2A). Although the proportion
of nausea and/or vomiting for the 50-mg
biweekly dose was greater than for the
30-mg weekly dose, it also declined over
the study period (Fig. 2B). Subjects re-
ceivingthe100-mgmonthlydosealsoex-
perienced higher rates of nausea and/or
vomiting, with peak incidence occurring
following each monthly dose administra-
tion. The overall rate was higher for
100-mg monthly than for the other albi-
glutidegroups(Fig.2C).Theincidenceof
nausea and/or vomiting with exenatide
reached 20% by week 2, increased at
week5toapeakincidenceof29%(dueto
label-based titration), and also declined
over the study period (Fig. 2E).
Other adverse events were less com-
mon than GI-related events and were
similar across groups with no dose-
dependent trends. Documented hypogly-
cemia was not increased with albiglutide
(0–3.1%) relative to placebo (3.9%) and
exenatide (2.9%). Cardiac-related ad-
verse events (eight subjects; six assessed
as severe) were distributed across groups,
with no dose-dependent trends (online
appendix 5). No episodes of pancreatitis
were reported.
Eight subjects (2.5%) had conﬁrmed
positive anti-albiglutide antibodies at
least once in the placebo and albiglutide
arms after baseline measurement. How-
ever, two subjects tested positive prior to
albiglutide treatment, and one subject
whotestedpositivereceivedplacebo.The
remaining ﬁve albiglutide-positive sub-
jects were detected in the weekly and bi-
weekly arms. The appearance of anti-
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Figure 2—Time course of nausea and vomiting as adverse events. The
percentageofsubjectsexperiencingvomitingwithorwithoutnausea(o)
or nausea ( ) adverse events during each week of the 16-week trial for
albiglutide 30 mg weekly (A), albiglutide 50 mg biweekly (B), albig-
lutide 100 mg monthly (C), placebo (D), and exenatide (E).
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transient: one subject remained positive
at week 27. Antibodies were non-
neutralizing and low titer and showed
cross-reactivity with GLP-1 in four of ﬁve
subjects. There was no obvious associa-
tion between the presence of anti-
albiglutide antibodies and either efﬁcacy
or safety.
Injection site local skin reactions,
most of which were small, were observed
in the study and were more common in
the albiglutide groups (2.9–28.6%) com-
pared with placebo (5.9%) and exenatide
(2.9%). Injection site reactions tended to
occur once per person in subjects receiv-
ing 30 mg albiglutide and approximately
twice per person in subjects receiving
higher albiglutide doses. Skin reactions
were not associated with positive IgE an-
tibodies or neutralizing antibodies and
did not worsen upon repeated dosing or
exhibit dose dependency. No systemic al-
lergic reactions attributable to albiglutide
were observed.
Pharmacokinetics
Albiglutide exhibited a plasma half-life of
5 days. Steady-state albiglutide levels
were reached within 4 to 5 weeks of the
ﬁrst dose (online appendix 6). Greater
peak/troughﬂuctuationsincirculatingal-
biglutide concentrations were observed
with less frequent administration of
higher doses.
CONCLUSIONS — In this study, the
dose- and time-dependent effects of albi-
glutide, a long-acting GLP-1 receptor ag-
onist, was evaluated to identify potential
dose regimens for future studies. Within
each dose schedule, albiglutide was asso-
ciated with generally dose-dependent
A1C reductions that were signiﬁcantly
different from placebo. Maximum doses
in each schedule (albiglutide 30 mg
weekly, 50 mg biweekly, and 100 mg
monthly) elicited similar responses in
A1C, providing meaningful reductions
within the range of 0.8–0.9% from a
mean baseline A1C of 8.0%.
Albiglutide also signiﬁcantly reduced
FPG at week 16 compared with placebo,
with reductions observed at the time of
the ﬁrst assessment (2 weeks postdose).
In a previous study, FPG reductions were
observed as early as 2 days following a
single dose (20).
Variability in glycemic response ap-
pearedtoberelatedtocirculatingconcen-
trationsofalbiglutide.Withaplasmahalf-
life of 5 days and at doses sufﬁcient to
achieve consistent therapeutic response
(i.e., 30 mg), weekly dosing provided
consistent FPG reduction. Greater FPG
ﬂuctuations were observed following bi-
weeklyormonthlydosing,despitesimilar
A1C reductions.
Albiglutide 30-mg weekly dosing
elicited steady and consistent improve-
ments in FPG reductions, with a more fa-
vorable nausea/vomiting proﬁle than
exenatide. When dosed biweekly, 50 mg
albiglutide also improved glycemic in-
dexes but with higher GI adverse event
rates, possibly related to the higher initial
dose.Inalldosingschedules,ratesofnau-
sea and vomiting declined over time.
However, when dosed monthly, albig-
lutide did not produce stable FPG reduc-
tions between dosing and was associated
withhigherGIeventrates.Theincreasein
FPG ﬂuctuation and GI events in the bi-
weekly and monthly regimens is likely
due to ﬂuctuations in plasma albiglutide
concentrations resulting from less fre-
quentdosing.Anescalating-dosetitration
for the biweekly regimen might have re-
sulted in a lower frequency of GI events.
This approach may be tested in future
studies to explore the possibility of using
biweekly dosing as a maintenance option
in patients who respond well and tolerate
the initial weekly regimen.
Mechanistically, the reasons for dif-
ferences in the tolerability of albiglutide
and exenatide are unknown but may be
due to differences in pharmacokinetics,
including gradual absorption (Tmax is 3
days vs. 2.1 h for albiglutide and ex-
enatide, respectively) and a long plasma
half-life of 5 days resulting in a steady
state achieved after 4–5 doses for 30 mg
albiglutide weekly. The slow accumula-
tion of albiglutide may ameliorate GI
intolerability often observed with ex-
enatide, and albiglutide’s relative imper-
meancetothecentralnervoussystemmay
result in a more benign proﬁle with re-
spect to nausea and vomiting than ex-
enatide (21).
Weight loss was similar across albig-
lutide arms and numerically less than
with exenatide, which had a higher base-
line BMI. Exploratory post hoc analyses
indicated that there was no obvious cor-
relation between reduction in A1C and
weight loss for all albiglutide doses (data
not shown). However, larger and longer-
term studies will determine the true effect
on weight and cardiometabolic parameters.
Immunogenicity was closely moni-
tored owing to the possible appearance of
neutralizing antibodies or the develop-
ment of immediate hypersensitivity reac-
tions. In this study, anti-albiglutide
antibodies were detected in 2.5% (n  8)
ofsubjects.However,theobservationthat
positive titers of anti-albiglutide antibod-
iesweredetectedinthreesubjectsatbase-
line suggests that the immunogenicity
rate may be overestimated. Exenatide,
which has 53% homology to human
GLP-1 (14), is associated with antibody
development following administration
withtwice-daily(15–18)andweekly(25)
formulations (40%). Antibody forma-
tion may attenuate efﬁcacy, especially
among patients developing high levels of
anti-exenatide antibodies (25).
There are limitations to this phase II
study. First, the number of subjects in
each arm is relatively small compared
with phase III studies. Second, relative to
the number of subjects, the dropout rate
was high owing to adverse events, loss to
follow-up, and voluntary withdrawals.
Third, the duration of active treatment
was 16 weeks, so the magnitude or dura-
bility of response cannot be fully appreci-
ated. Fourth, no escalating doses were
tested for biweekly and monthly dosing,
which may have attenuated GI adverse
events and FPG ﬂuctuations. Finally, be-
cause exenatide was administered open
label, formal statistical comparisons were
not conducted between exenatide and
albiglutide.
In conclusion, albiglutide improved
glucosecontrolinadose-dependentman-
ner when given weekly and biweekly.
Higher monthly doses of albiglutide were
efﬁcacious, but their use was constrained
by the higher frequency of GI-related ad-
verse events. Weekly albiglutide signiﬁ-
cantlyimprovedglycemiccontrolwithan
acceptable safety and tolerability proﬁle
and modest weight loss without increas-
ing the risk of hypoglycemia or immuno-
logical response in subjects with type 2
diabetes. Future studies may elucidate
whether titration dosing or biweekly
scheduling could be options for patients
who respond to and tolerate the initial
weekly regimen.
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